Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CHD1L CRISPR/Cas9 KO Plasmid (h): sc-404840
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CHD1L CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CHD1L genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CHD1L Antibody (2170C3a): sc-81065
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CHD1L CRISPR/Cas9 KO Plasmid (h) | sc-404840 | 20 µg | $397.00 |
Overview
CHD1L (chromodomain helicase DNA binding protein 1-like) is an ATP-dependent chromatin remodeler implicated in regulating DNA accessibility during transcription, replication stress responses, and DNA damage repair. Through its helicase/ATPase activity and chromodomain-mediated interactions, CHD1L helps coordinate chromatin dynamics that influence genome stability and cell-cycle progression. Altered CHD1L expression or copy-number gain has been reported in multiple tumor contexts and is frequently studied for its connections to oncogenic transcriptional programs, replicative stress tolerance, and invasive phenotypes. These features make CHD1L a relevant target for dissecting chromatin-dependent control of gene expression and DNA repair pathway choice.
CHD1L CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CHD1L gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CHD1L together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CHD1L open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CHD1L protein expression.
This CRISPR knockout system enables efficient generation of CHD1L-deficient cell models for investigation of CHD1L signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CHD1L exon(s) critical for CHD1L function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CHD1L genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CHD1L CRISPR/Cas9 KO Plasmid (h) and CHD1L CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CHD1L locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CHD1L HDR Plasmid (h) and CHD1L HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CHD1L homology arms to support homology-directed repair at defined CHD1L target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.